Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$337.84
Open:$335.90
Day's Low:$334.31
Day's High:$342.09
Bid / Ask:-
Market Cap:64.98B
Enterprise Value:76.30B
52-Week Range
52-Week Low:$244.82
52-Week High:$377.54
Current position in 52-week range
52w Low-52w High
50-Day Avg:$323.77
200-Day Avg:$317.00
Volume
Volume Today:1,647,541
Avg Volume (3m):1,313,660
Avg Volume (10d):1,185,470
52-Week Change:-1.94%
vs S&P 500, 52 weeks:-
Beta:0.57
Valuation Multiples
P/E (trailing):25.28
Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 5, 2026. The P/E is the price divided by that EPS.
P/E (forward):17.23
PEG Ratio:0.71
Price / Book:21.30
Price / Sales (TTM):0.20
EV / Revenue:0.23
EV / EBITDA:13.76
Dividends
Current yield:0.71%
Annual Dividend Rate:$2.40
Dividend Trailing:$2.35
Yield Trailing:0.70%
5-Year Avg Yield:0.91%
Payout Ratio:17.45%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):332.77B
Gross Profit:13.18B
EBITDA:5.55B
Net Income (TTM):2.62B
Rev Growth (YoY):+5.10%
Earnings Growth (YoY):+11.90%
Quarterly earnings growth (YoY):+11.10%
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$13.47
Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 5, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$19.76
Revenue Per Share:$1,715.73
Cash Per Share:-
Book Value:$15.99
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:2.82B
Total Debt:14.46B
Net Debt (Debt - Cash):11.65B
Debt / Equity:446.52%
Current Ratio:0.94
Quick Ratio:0.48
Cash Flows
Operating Cash Flow:4.82B
Free Cash Flow (FCF):2.04B
FCF Yield (FCF / Market Cap):-
Enterprise Value:76.30B
EV / Revenue:0.23
EV / EBITDA:13.76
Profitability
ROE (Return on Equity):96.87%
ROA (Return on Assets):3.56%
P/E (trailing):25.28
P/E (forward):17.23
Price / Book:21.30
PEG Ratio:0.71
52-Week Change:-1.94%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$13.47
Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 5, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$19.76
P/E (forward):17.23
PEG Ratio:0.71
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$1,715.73
Cash Per Share:-
Book Value:$15.99
Cash Flows (TTM)
Free Cash Flow:2.04B
Operating Cash Flow:4.82B
EBITDA:5.55B
Total Revenue (TTM):332.77B
Net Income (TTM):2.62B
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:190,827,165
Float (free shares):180,249,615
Short interest (shares):3,932,007
Short % of float:-
Short Ratio (days to cover):3.16
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
Cencora, Inc. (COR) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Senior VP Of Investor Relations & Enterprise Productivity and Treasury
-
-
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
No card. No spam.
Cencora, Inc. (COR): Quantitative Analysis
Cencora, Inc. (COR) — Healthcare — Medical Distribution. COR is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, COR has returned +1.3% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
COR ranks 188 of 461 on today's multifactor score, and 23 of the 55 Healthcare companies that score. Its strongest factor is growth (Z 0.94, ranked 41 of 489); its weakest is quality (Z -0.90, ranked 446 of 468). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
According to Nasdaq's public calendar (checked on Nov 4, 2026), Cencora will report its next earnings on Nov 4, 2026, before the US market opens. The date is announced by the company itself and can change. Of its last 12 earnings announcements: 11 before the open (and 1 with no time on the filing) (SEC filings through Oct 21, 2026). COR earnings dates and times, quarter by quarter →
What is Cencora's P/E ratio?
Cencora's P/E (price over earnings per share for the last twelve months) is 25.3 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Jun 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Cencora is below its sector median. Healthcare stocks, company by company →
Where does Cencora rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, Cencora ranks 188 of 461, and 23 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have Cencora insiders bought or sold shares?
The latest open-market purchase of Cencora shares filed with the SEC (Form 4) was on Jun 22, 2026, by a director, for $149k. The latest sale was on Oct 1, 2026, by an officer, for $299k. In total, from August 2025 through Nov 3, 2026: 3 purchases and 16 sales by directors, officers and large shareholders. All COR insider trades →
Does Cencora pay a dividend?
Yes. Its dividend yield is 0.71% at the Nov 3, 2026 close (annual dividend of $2.40 per share). The latest recorded ex-dividend date is Aug 14, 2026.
What sector is Cencora in, and which index?
Cencora is classified in the Healthcare sector (industry: Medical Distribution), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.